We’re still figuring out the side effects of GLP-1 weight-loss drugs
This piece examines the emerging side effects and potential longevity benefits of GLP-1 weight-loss drugs like Ozempic and Wegovy. It notes that while these drugs are highly effective, researchers are still uncovering the full scope of their long-term health impacts.
Why it matters
With millions of people using GLP-1 agonists, understanding the full spectrum of side effects is essential for public health and patient safety.
Could the drugs affect hair, nails, and vision?
This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age .
Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than similar individuals who take a placebo, according to findings from Eli Lilly and Novo Nordisk, two pharmaceutical companies that make the drugs.
I’ve heard people in the aging field describe GLP-1s as longevity drugs for a while now (even if they only benefit people who are overweight or diabetic in the first place). This latest announcement comes after we’ve seen a raft of other benefits associated with taking these drugs. But there are also some weird side effects.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in